Issue 42

EXCLUSIVE: Beckley Psytech’s CEO Cosmo Feilding Mellen on raising US$80 million

Beckley Psytech has announced the completion of its oversubscribed financing round, with US$80m raised.  The company is currently conducting clinical trials with low doses of psilocybin, as a pharmacological intervention without a psychotherapy component. There are also plans to start Phase I clinical trials into its intranasal 5-MeO-DMT formulation later this year.

PSYCH spoke with Beckley Psytech’s CEO Cosmo Feilding Mellen, regarding the company’s investors, mission and revived interest in the field – dubbed the psychedelic renaissance.

Read More

WHY THE CANNABIS INDUSTRY SHOULD MAKE ROOM FOR MUSHROOMS

Medicinal cannabis companies are increasingly looking to psilocybin to diversify their portfolio.

Read More

ATAI LIFE SCIENCES CREATES SALVIA DIVINORUM SUBSIDIARY

Revixia Life Sciences to treat depression and substance use disorder, with clinical trials planned for 2022.

Read More

The Psychedelics As Medicine Report

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.

Download Report

BUSINESS AND INVESTMENT

Origin Therapeutics to invest US$5.1m in psychedelics companies.

Awakn Life Sciences starts trading on OTCQB.

Field Trip shares financial update with C$100m in cash.

MindMed reports cash balance of US$157m in Q2 2021.

atai Life Sciences shares Q2 2021 financial results.

Filament Health shares financial results for Q2 2021.

Mydecine releases Q2 2021 financial results.

Psilera starts preclinical trials to combat alcohol use disorder.

Health Canada approves Diamond Therapeutics’ low-dose psilocybin clinical trial.

Entheon Biomedical sponsors clinical trials into the effects of ketamine on the brain’s electrical activity.

Psyched Wellness files patents for amanita-derived compound.

PsyBio Therapeutics patents tryptamine production method.

Cybin files patent for pre-clinical and research programme methodology.

Israeli team aims to treat neurological disorders with psychedelics.

Nushuma to open new psychedelic clinic in New York.

What do you really know about psychedelics and psychedelic stocks?

Advanced Brain + Body Clinic to open a second ketamine therapy clinic.

RESEARCH AND SCIENCE

We just got closer to understanding why ketamine is such a powerful antidepressant.

Ketamine or esketamine do not pose adverse cognitive effects in patients with depression: study.

Bexson Biomedical to research subcutaneous psychedelic formulations

‘Stuck in a cul-de-sac’: Researchers are finally breaking away from the central dogma of depression.

Psychedelic research leaves out people of colour.

Wuhan General Group to set up research facilities in South Africa.

REGULATION AND LEGISLATION

Congressman who voted against psychedelics amendment says MDMA therapy ‘sounds amazing’.

Ann Arbor city council declares psychedelics awareness month for September.

Meet two Australians pushing for medicinal psychedelics to become mainstream.

Washington governor unveils new process to commute hundreds of drug possession sentences.

Biden ‘exploring’ clemency for federal drug crimes, Psaki says.

Partner with us